Published in In Vivo, November 2020
Authors: Dr. Oded Ben-Joseph and Dr. Mykel Robble
Transactional activity – mergers, acquisitions and alliances – is an important tool that allows big pharma companies to maintain a competitive edge, ensure a healthy pipeline and reduce developmental risk by allocating resources towards promising candidates. Importantly, these transactions allow large companies to access innovation, typically provided by smaller entrepreneurial players. For investors in the target companies, the prospect of an acquisition or partnership represents an attractive exit window with substantial returns and far increased likelihood that candidate therapeutics reach patients. There are innumerable benefits of early partnerships for earlier stage target companies. Beyond providing a flow of cash, partnership transactions enable rapid discovery, development and scale-up, access to knowledge and expertise, essential resources, third-party validation and credibility and overall risk mitigation.
Understanding the rationale behind these transactions and the intended strategic direction of acquirers is key for CEOs when considering how to position their companies in a market-aligned manner. To that effect, Outcome Capital analyzed transactional activity by the largest biopharmaceutical companies in the three-and-a-half-year period between January 2017 and June 2020. Our analysis describes the type and frequency of acquisitions and collaborations in the biopharmaceutical industry and reveals sectors and stages of development in which transactional activity in concentrated.
June 23, 2021, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies in aerospace, defense and government services, technology, and life sciences, is pleased to announce that Nova Technologies (“Nova” or the “Company”) has received an equity investment from Slate Capital Group, a private equity firm based in Baltimore, MD, […]Read More
June 17, 2021 09:40 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Outcome Capital, a specialized advisory and investment banking firm that serves middle market companies in the life science and technology segments, today announced that Veranex, a newly formed concept-to-commercialization service provider dedicated to the medtech industry, has acquired Boston Healthcare Associates (BHA), a global strategy consulting […]Read More
Outcome Capital Life Science Market Pulse August 2021 Click to view our LifeSciences Pulse NewsletterDownload